Opinion|Videos|October 28, 2024
Clinical Experience with Capivasertib
Panelists discuss their clinical experiences with capivasertib, focusing on patient tolerability and the management of adverse effects associated with this targeted therapy.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Can you share your clinical experience with capivasertib and your patient’s tolerability?
Advertisement
Related to this article
Many patients with IDH-mutant glioma continued to receive vorasidenib as directed in the real-world GLIO-ADHERE claims analysis.
Mirdametinib produced stable disease or partial responses in adults and children with plexiform neurofibromas who had received another MEK inhibitor.
Longer follow-up of the phase 3 INDIGO trial showed that vorasidenib lowered seizure rates in IDH-mutant glioma, an effect driven by oligodendroglioma.
Many patients with BRAF-altered pediatric low-grade glioma stayed off therapy after planned tovorafenib cessation in the 4-year FIREFLY-1 update.
Sarah Goldberg, MD, MPH, details how clinicians can choose among frontline regimens, act on resistance mechanisms, and incorporate ADCs and newer agents across the spectrum of EGFR-mutated NSCLC.
The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.
Serial amino acid PET flagged responses earlier than MRI in IDH-mutant glioma treated with vorasidenib, interim data show.
Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.
Advertisement
Advertisement
Trending on OncLive
1
Dr Johnson on Immune Activation With Indoximod-Based Chemo-Immunotherapy in Recurrent Ependymoma
2
Tovorafenib Sustains Treatment-Free Intervals in R/R BRAF-Altered Pediatric Low-Grade Glioma
3
Dr Miller on Whole Genome Sequencing of CSF ctDNA in High-Grade Glioma
4
Patient Preferences Steer Decisions as Options Multiply Across EGFR-Mutated NSCLC
5